Human Molecular Genetics Advance Access published online on August 22, 2005
Human Molecular Genetics, doi:10.1093/hmg/ddi315
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030, Texas
* To whom correspondence should be addressed. Stroke is the leading cause of severe disability and the third leading cause of death, accounting for 1 of every 15 deaths in the United States. We investigated the association of polymorphisms in the soluble epoxide hydrolase gene (EPHX2) with incident ischemic stroke in African-Americans and Whites. Twelve single nucleotide polymorphisms (SNPs) spanning EPHX2 were genotyped in a case-cohort sample of 1,336 participants from the Atherosclerosis Risk in Communities (ARIC) study. In each racial group, Cox proportional hazard models were constructed to assess the relationship between incident ischemic stroke and EPHX2 polymorphisms. A score test method was used to investigate the association of common haplotypes of the gene with risk of ischemic stroke. In African-Americans, two common EPHX2 haplotypes with significant and opposing relationships to ischemic stroke risk were identified. In Whites, two common haplotypes showed suggestive indication of an association with ischemic stroke risk but, as in African-Americans, these relationships were in opposite direction. These findings suggest that multiple variants exist within or near the EPHX2 gene, with greatly contrasting relationships to ischemic stroke incidence; some associated with a higher incidence, others with a lower incidence.
Received June 23, 2005
Revised August 2, 2005
Accepted August 10, 2005
Article
The Soluble Epoxide Hydrolase Gene Harbors Sequence Variation Associated with Susceptibility to and Protection from Incident Ischemic Stroke
2 Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, the University of North Carolina at Chapel Hill; Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina
3 Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center, Houston, Texas
4 Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
5 Department of Epidemiology, School of Public Health, the University of North Carolina at Chapel Hill
6 Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina
Myriam Fornage, E-mail: myriam.fornage{at}uth.tmc.edu
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. N. Simpkins, R. D. Rudic, D. A. Schreihofer, S. Roy, M. Manhiani, H.-J. Tsai, B. D. Hammock, and J. D. Imig Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural Protection Am. J. Pathol., June 1, 2009; 174(6): 2086 - 2095. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Dmitrieva, C. A. Hinojos, M. L. Grove, R. J. Bell, E. Boerwinkle, M. Fornage, and P. A. Doris Genome-Wide Identification of Allelic Expression in Hypertensive Rats Circ Cardiovasc Genet, April 1, 2009; 2(2): 106 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Behm, A. Ogbonna, C. Wu, C. L. Burns-Kurtis, and S. A. Douglas Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 231 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P Burdon, A. B Lehtinen, C. D Langefeld, J. J. Carr, S. S Rich, B. I Freedman, D. Herrington, and D. W Bowden Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 128 - 134. [Abstract] [PDF] |
||||
![]() |
A. Gschwendtner, S. Ripke, T. Freilinger, P. Lichtner, B. Muller-Myhsok, H.-E. Wichmann, T. Meitinger, and M. Dichgans Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With an Increased Risk of Ischemic Stroke in White Europeans Stroke, May 1, 2008; 39(5): 1593 - 1596. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Corenblum, V. E. Wise, K. Georgi, B. D. Hammock, P. A. Doris, and M. Fornage Altered Soluble Epoxide Hydrolase Gene Expression and Function and Vascular Disease Risk in the Stroke-Prone Spontaneously Hypertensive Rat Hypertension, February 1, 2008; 51(2): 567 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. P. Koerner, R. Jacks, A. E. DeBarber, D. Koop, P. Mao, D. F. Grant, and N. J. Alkayed Polymorphisms in the Human Soluble Epoxide Hydrolase Gene EPHX2 Linked to Neuronal Survival after Ischemic Injury J. Neurosci., April 25, 2007; 27(17): 4642 - 4649. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Lee, K. E. North, M. S. Bray, M. Fornage, J. M. Seubert, J. W. Newman, B. D. Hammock, D. J. Couper, G. Heiss, and D. C. Zeldin Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study Hum. Mol. Genet., May 15, 2006; 15(10): 1640 - 1649. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Pastinen, B. Ge, S. Gurd, T. Gaudin, C. Dore, M. Lemire, P. Lepage, E. Harmsen, and T. J. Hudson Mapping common regulatory variants to human haplotypes Hum. Mol. Genet., December 15, 2005; 14(24): 3963 - 3971. [Abstract] [Full Text] [PDF] |
||||







